Pyrazinamide ๐
๐ About
Always check the BNF link here.
- ๐ Key component of standard anti-tuberculosis regimens.
- ๐งช Shortens treatment duration by sterilising intracellular organisms in acidic environments.
โ๏ธ Action
- ๐ฆ Bactericidal โ taken up by macrophages and acts against intracellular mycobacteria.
- ๐ก๏ธ Most active at acidic pH (e.g., within tuberculous lesions).
๐งช Properties
- ๐ง Good CSF penetration when meninges are inflamed.
- โฑ๏ธ Plasma half-life: ~8โ11 hours.
๐ Indications
- ๐ฅ Always given in combination with rifampicin and isoniazid (ยฑ ethambutol) as part of first-line TB therapy.
๐ Interactions
- ๐ See BNF for full details.
โ ๏ธ Cautions
- ๐ฆด Use cautiously in patients with a history of gout (โ uric acid levels).
- ๐งช Monitor LFTs โ especially in those with suspected or pre-existing liver disease.
๐ Dose Range (monitor LFTs)
| Patient weight | Dose | Frequency | Route |
| < 50 kg | 1.5 g | OD | PO |
| > 50 kg | 2 g | OD | PO |
โ Contraindications
- ๐ซ Acute porphyria.
- ๐ซ Severe hepatic impairment.
๐ฅ Side Effects
- ๐งช Hepatotoxicity (major limiting factor) โ monitor LFTs.
- ๐ฆด Arthralgia, hyperuricaemia, acute gout.
- ๐ก๏ธ Drug fever, rash, thrombocytopenia.
- ๐ง Rare: dysuria, sideroblastic anaemia, interstitial nephritis.